Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Essex Bio-TechnologyHKSE:01061 +0.88%86 Days Inventory is 118.25 as of Jun. 2026, which is 28% below its 10-year median of 164.70. GuruFocus rates HKSE:01061 with a GF Score™ of 86/100 and a GF Value™ of HK$3.13 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 918 Drug Manufacturers companies, Essex Bio-Technology ranks better than 67.65% on this metric.
The historical rank and industry rank for Essex Bio-Technology's Days Inventory or its related term are showing as below:
HKSE:01061'
s Days Inventory Range Over the Past 10 Years
Min: 124.33 Med: 164.7 Max: 258.63
Current: 124.33
During the past 13 years, Essex Bio-Technology's highest Days Inventory was 258.63. The lowest was 124.33. And the median was 164.70.
HKSE:01061's Days Inventory is ranked better than 67.65% of 918
companies
in the Drug Manufacturers industry
Industry Median: 164.53
vs HKSE:01061: 124.33
Inventory Turnover measures how fast the company turns over its inventory within a year.
Essex Bio-Technology's Inventory Turnover for the
six
months ended in Jun. 2026 was 1.54.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Essex Bio-Technology's Inventory-to-Revenue for the
six
months ended in Jun. 2026 was 0.11.
Essex Bio-Technology (HKSE:01061) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Essex Bio-Technology's Inventory Turnover for the
six
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Essex Bio-Technology's Inventory to Revenue for the
six
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Essex Bio-Technology Days Inventory Related Terms
Essex Bio-Technology Days Inventory Historical Data
* Premium members only.
The historical data trend for Essex Bio-Technology's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Essex Bio-Technology's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Essex Bio-Technology Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Essex Bio-Technology's Days Inventory distribution charts can be found below:
* The bar in red indicates where Essex Bio-Technology's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Essex Bio-Technology (HKSE:01061) has a Days Inventory of 118.25 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Essex Bio-Technology and its competitors. This is 28% below median its historical median of 164.70. Over the past decade, Essex Bio-Technology's Days Inventory has ranged from 124.33 to 258.63. According to the industry distribution chart, Essex Bio-Technology ranks #297 out of 918 companies in the Drug Manufacturers industry, placing it in the top 32.4%.
Is Essex Bio-Technology's Days Inventory too high?
Essex Bio-Technology's current Days Inventory of 118.25 is 28% below median its 10-year median of 164.70. Over the past 10 years, this metric has ranged from a low of 124.33 to a high of 258.63. The Drug Manufacturers industry median Days Inventory is 164.53. Essex Bio-Technology's value of 118.25 is 28.1% below this industry median. Based on the distribution chart, Essex Bio-Technology ranks #297 out of 918 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Essex Bio-Technology has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Essex Bio-Technology's Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Essex Bio-Technology ranks #297 out of 918 companies for Days Inventory. This puts Essex Bio-Technology in the upper half of its industry. The industry median Days Inventory is 164.53. Essex Bio-Technology's value of 118.25 is 28.1% below this benchmark. Historically, Essex Bio-Technology's own Days Inventory has ranged from 124.33 to 258.63 over the past decade. While the company's 10-year median is 164.70 vs. the industry median of 164.53, Essex Bio-Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.53, based on 918 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Essex Bio-Technology's current Days Inventory of 118.25 is 28.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Essex Bio-Technology and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Essex Bio-Technology's current Days Inventory is 118.25, which is 28% below median its own 10-year median of 164.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Essex Bio-Technology stock overvalued right now?
Based on GuruFocus' analysis, Essex Bio-Technology (HKSE:01061) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.13, compared to a current price of HK$2.29 — trading 26.8% below its estimated fair value. The current Days Inventory is 118.25, which is 28% below median its 10-year median of 164.70 and 28.1% below the Drug Manufacturers industry median of 164.53. Essex Bio-Technology's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Essex Bio-Technology (HKSE:01061), the current Days Inventory is 118.25 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Essex Bio-Technology (HKSE:01061) Overvalued in 2026?
Based on GuruFocus' analysis, Essex Bio-Technology stock appears to be undervalued.
The current stock price of HK$2.29 is trading 26.8% below its estimated GF Value™ of HK$3.13.
GuruFocus considers Essex Bio-Technology to be Modestly Undervalued.
Key valuation signals for HKSE:01061:
Days Inventory: 118.25 (28% below median its 10-year median of 164.70)
GF Value™: HK$3.13 vs. price of HK$2.29 (26.8% below fair value)
Industry Position: 28.1% below the Drug Manufacturers median (#297 of 918)
No single metric tells the full story. See the HKSE:01061 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture, and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, and Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel, and mouthwash. The majority of the group's revenue comes from the PRC, also operates in Hong Kong and other countries.
86GF Score
Get the complete analysis for HKSE:01061
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01061 has been successfully added to your 
